News | November 10, 2023
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo will respond to the US FDA within the stipulated timelines
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
